Histone H2AX phosphorylation as a molecular pharmacological marker for DNA interstrand crosslink cancer chemotherapy.

The aims of this study were to investigate mechanisms of action involved in H2AX phosphorylation by DNA interstrand crosslinking (ICL) agents and determine whether gammaH2AX could be a suitable pharmacological marker for identifying potential ICL cellular chemosensitivity. In normal human fibroblasts, after treatment with nitrogen mustard (HN2) or cisplatin, the peak gammaH2AX response was detected 2-3 h after the peak of DNA ICLs measured using the comet assay, a validated method for detecting ICLs in vitro or in clinical samples. Detection of gammaH2AX foci by immunofluorescence microscopy could be routinely detected with 6-10 times lower concentrations of both drugs compared to detection of ICLs using the comet assay. A major pathway for repairing DNA ICLs is the initial unhooking of the ICL by the ERCC1-XPF endonuclease followed by homologous recombination. HN2 or cisplatin-induced gammaH2AX foci persisted significantly longer in both, ERCC1 or XRCC3 (homologous recombination) defective Chinese hamster cells that are highly sensitive to cell killing by ICL agents compared to wild type or ionising radiation sensitive XRCC5 cells. An advantage of using gammaH2AX immunofluorescence over the comet assay is that it appears to detect ICL chemosensitivity in both ERCC1 and HR defective cells. With HN2 and cisplatin, gammaH2AX foci also persisted in chemosensitive human ovarian cancer cells (A2780) compared to chemoresistant (A2780cisR) cells. These results show that gammaH2AX can act as a highly sensitive and general marker of DNA damage induced by HN2 or cisplatin and shows promise for predicting potential cellular chemosensitivity to ICL agents.

[1]  Michel Nussenzweig,et al.  H2AX: the histone guardian of the genome. , 2004, DNA repair.

[2]  Kai Rothkamm,et al.  Evidence for a lack of DNA double-strand break repair in human cells exposed to very low x-ray doses , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[3]  S. Madhusudan,et al.  Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. , 2007, Cancer treatment reviews.

[4]  U. Veronesi,et al.  Oxford textbook of oncology , 1996 .

[5]  P. Olive,et al.  Radiation Sensitivity, H2AX Phosphorylation, and Kinetics of Repair of DNA Strand Breaks in Irradiated Cervical Cancer Cell Lines , 2004, Cancer Research.

[6]  R. Bonner,et al.  Histone H2AX phosphorylation is dispensable for the initial recognition of DNA breaks , 2003, Nature Cell Biology.

[7]  D. Scudiero,et al.  New colorimetric cytotoxicity assay for anticancer-drug screening. , 1990, Journal of the National Cancer Institute.

[8]  M. Sasaki,et al.  Recombination repair pathway in the maintenance of chromosomal integrity against DNA interstrand crosslinks , 2004, Cytogenetic and Genome Research.

[9]  Ling-hua Meng,et al.  Emerging cancer therapeutic opportunities target DNA-repair systems. , 2006, Trends in pharmacological sciences.

[10]  D. Schild,et al.  Recombinational DNA repair and human disease. , 2002, Mutation research.

[11]  Wolf-Dietrich Heyer,et al.  Homologous recombination in DNA repair and DNA damage tolerance , 2008, Cell Research.

[12]  P. Olive,et al.  Phosphorylation of histone H2AX as a measure of radiosensitivity. , 2004, International journal of radiation oncology, biology, physics.

[13]  J. Hartley,et al.  Chemosensitivity of primary human fibroblasts with defective unhooking of DNA interstrand cross-links. , 2007, Experimental cell research.

[14]  P. McHugh,et al.  Defining the Roles of Nucleotide Excision Repair and Recombination in the Repair of DNA Interstrand Cross-Links in Mammalian Cells , 2000, Molecular and Cellular Biology.

[15]  C. Craddock,et al.  Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. , 2000, Blood.

[16]  V. Yamazaki,et al.  A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage , 2000, Current Biology.

[17]  S. Mogi,et al.  gamma-H2AX formation in response to interstrand crosslinks requires XPF in human cells. , 2006, DNA repair.

[18]  S. Madhusudan,et al.  The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer. , 2005, Cancer treatment reviews.

[19]  R C Young,et al.  Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. , 1987, Cancer research.

[20]  W. Bonner,et al.  γ-H2AX in Cancer Cells: A Potential Biomarker for Cancer Diagnostics, Prediction and Recurrence , 2006, Cell cycle.

[21]  Stephen J Kron,et al.  Histone H2AX Phosphorylation as a Predictor of Radiosensitivity and Target for Radiotherapy* , 2004, Journal of Biological Chemistry.

[22]  R. Kanaar,et al.  Repair of DNA interstrand cross-links. , 2001, Mutation research.

[23]  P. Olive,et al.  Phosphorylated histone H2AX in relation to cell survival in tumor cells and xenografts exposed to single and fractionated doses of X-rays. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[24]  J. Surrallés,et al.  New Roads to FA/BRCA Pathway: H2AX , 2007, Cell cycle.

[25]  J. Hoeijmakers,et al.  The Structure-Specific Endonuclease Ercc1-Xpf Is Required To Resolve DNA Interstrand Cross-Link-Induced Double-Strand Breaks , 2004, Molecular and Cellular Biology.

[26]  M. Grompe,et al.  Repair Kinetics of Genomic Interstrand DNA Cross-Links: Evidence for DNA Double-Strand Break-Dependent Activation of the Fanconi Anemia/BRCA Pathway , 2004, Molecular and Cellular Biology.

[27]  J. Ledermann,et al.  Enhanced repair of DNA interstrand crosslinking in ovarian cancer cells from patients following treatment with platinum-based chemotherapy , 2007, British Journal of Cancer.

[28]  M. Waring,et al.  Sequence-selective interaction of the minor-groove interstrand cross-linking agent SJG-136 with naked and cellular DNA: footprinting and enzyme inhibition studies. , 2005, Biochemistry.

[29]  V. Natale,et al.  H2AX phosphorylation within the G1 phase after UV irradiation depends on nucleotide excision repair and not DNA double-strand breaks. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[30]  L. Kèlland,et al.  The resurgence of platinum-based cancer chemotherapy , 2007, Nature Reviews Cancer.

[31]  T. Furukawa,et al.  Resistance to cisplatin. , 1999, Anti-cancer drug design.

[32]  Z. Darżynkiewicz,et al.  Assessment of histone H2AX phosphorylation induced by DNA topoisomerase I and II inhibitors topotecan and mitoxantrone and by the DNA cross‐linking agent cisplatin , 2004, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[33]  P. McHugh,et al.  Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin. , 2002, Nucleic acids research.

[34]  G. Strathdee,et al.  A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer , 1999, Oncogene.